Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,774 GBX | +0.71% | +4.02% | +22.29% |
05-08 | Gsk plc Announces Board Committee Changes | CI |
05-08 | GSK : Receives a Buy rating from Bernstein | ZD |
Sales 2024 * | 31.61B 39.48B 3,161B | Sales 2025 * | 33.56B 41.91B 3,356B | Capitalization | 72.32B 90.33B 7,232B |
---|---|---|---|---|---|
Net income 2024 * | 5.59B 6.98B 559B | Net income 2025 * | 6.47B 8.08B 647B | EV / Sales 2024 * | 2.68 x |
Net Debt 2024 * | 12.3B 15.37B 1,230B | Net Debt 2025 * | 9.1B 11.37B 910B | EV / Sales 2025 * | 2.43 x |
P/E ratio 2024 * |
13
x | P/E ratio 2025 * |
11.2
x | Employees | 70,212 |
Yield 2024 * |
3.44% | Yield 2025 * |
3.57% | Free-Float | 94.38% |
Latest transcript on GSK plc
1 day | +0.71% | ||
1 week | +4.02% | ||
Current month | +6.01% | ||
1 month | +9.48% | ||
3 months | +7.42% | ||
6 months | +24.35% | ||
Current year | +22.29% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 30/04/10 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 30/04/23 |
James Ford
CMP | Compliance Officer | - | 31/07/95 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 30/04/23 |
Jonathan Symonds
CHM | Chairman | 66 | 31/08/19 |
Urs Rohner
BRD | Director/Board Member | 65 | 31/12/14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 0 M€ | +5.54% | - | |
2.51% | 0 M€ | +5.06% | - |
Date | Price | Change | Volume |
---|---|---|---|
08/05/24 | 1,774 | +0.71% | 6,684,171 |
07/05/24 | 1,761 | +1.59% | 14,302,770 |
03/05/24 | 1,734 | +0.29% | 4,237,170 |
02/05/24 | 1,728 | +1.38% | 6,275,228 |
01/05/24 | 1,705 | +1.91% | 5,851,371 |
Delayed Quote London S.E., May 08, 2024 at 04:35 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.29% | 90.35B | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.70% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- GSK Stock